Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosis Funding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF) Novo Holdings and HealthCap co-created Tribune in 2020 COPENHAGEN – March 24th, 2025 – Novo Holdings today announced its […]
